oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Urology.ORCID-id: 0000-0001-5533-7899
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Urology.ORCID-id: 0000-0003-0162-5881
Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
School of Medical Sciences, Örebro University, Örebro, Sweden. (Clinical Epidemiology and Biostatistics)
Visa övriga samt affilieringar
2020 (Engelska)Ingår i: Applied immunohistochemistry & molecular morphology (Print), ISSN 1541-2016, E-ISSN 1533-4058, Vol. 28, nr 3, s. 213-220Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed death 1, acts as a negative regulator of the antitumor T-cell-mediated immune response. The prognostic value of PD-L1 expression in renal cell carcinoma (RCC) has been controversial. In this study, the prognostic value of PD-L1 expression in RCC was evaluated by analyzing PD-L1 immunoreactivity in tumor cells and tumor-infiltrating immune cells (TIICs) in 346 RCC patients with long-term follow-up. PD-L1 positivity in tumor cells was associated with higher World Health Organization nucleolar grade (P<0.001), recurrence (P=0.011), and death due to RCC (P=0.031). PD-L1 positivity in TIICs was associated with higher nucleolar grade (P<0.001), higher T-stage (P=0.031), higher N-stage (P=0.01), recurrence (P=0.007), and death due to RCC (P=0.001). A significant positive association of time to cancer-specific death with both PD-L1-positive tumor cells and TIICs were also found. The data indicate that RCC patients with PD-L1-positive tumor cells and TIICs are at significant risk for cancer progression and the expression may be used as a complementary prognostic factor in the management of RCC patients.

Ort, förlag, år, upplaga, sidor
Lippincott Williams & Wilkins, 2020. Vol. 28, nr 3, s. 213-220
Nationell ämneskategori
Urologi och njurmedicin Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:oru:diva-74192DOI: 10.1097/PAI.0000000000000766PubMedID: 31058656OAI: oai:DiVA.org:oru-74192DiVA, id: diva2:1315265
Tillgänglig från: 2019-05-13 Skapad: 2019-05-13 Senast uppdaterad: 2020-03-17Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Carlsson, JessicaSundqvist, Pernilla

Sök vidare i DiVA

Av författaren/redaktören
Carlsson, JessicaSundqvist, Pernilla
Av organisationen
Institutionen för medicinska vetenskaperRegion Örebro län
I samma tidskrift
Applied immunohistochemistry & molecular morphology (Print)
Urologi och njurmedicinCancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 115 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf